The FDA made a major press announcement in 2017 about popular cancer drug Tasigna. The press announcement asserted Tasigna patients …
FDA Issues Updated Tasigna (Nilotinib) Label for Leukemia Patients
Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) usually face lifelong treatments to keep the disease in check. This …
Arteriosclerosis Studies Link Tasigna to Serious Heart Damage Risks
Coronary artery disease (also known as arteriosclerosis) is a condition that causes your blood vessels to thicken and grow stiff. …
Tasigna Removed From Several 2018 Drug Formulary Lists
It’s no secret that drug manufacturers and distributors earn incredible profit margins on medication sales. Even when generic versions are …
Chronic Myeloid Leukemia: Who’s At Risk, and What Are the Signs?
Chronic myeloid leukemia (CML) is a blood cancer that affects about 200,000 new people each year. This difficult-to-treat disease starts …
Study: Leukemia Treatment Tasigna May Treat Parkinson’s, Alzheimer’s
A June 2016 study looked at controversial leukemia treatment Tasigna (nilotinib) to measure its effect on Parkinson’s symptoms. According to …
We Translate Tasigna’s QT Prolongation Warning Into Plain English
The U.S. Food and Drug Administration approved leukemia drug Tasigna (generic name: nilotinib) in 2007. In 2015, however, the FDA …
FDA Approves Actemra for Cytokine Release Syndrome
In August, the U.S. Food and Drug Administration (FDA) approved Actemra to treat CAR T cell-induced cytokine release syndrome (CRS). …